US Patent Issued to Atea Pharmaceuticals on Feb. 18 for "Highly active compounds against COVID-19" (Massachusetts Inventors)

ALEXANDRIA, Va., Feb. 19 -- United States Patent no. 12,226,429, issued on Feb. 18, was assigned to Atea Pharmaceuticals Inc. (Boston).

"Highly active compounds against COVID-19" was invented by Jean-Pierre Sommadossi (Boston) and Adel Moussa (Burlington, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention is the use of a small group of purine nucleotide phosphoramidate disclosed herein or a pharmaceutically acceptable salt thereof in an effective amount for the treatment or prevention of the novel 2019 coronavirus disease (COVID-19) in a host, for example a human, in need thereof."

The patent was filed on July 24, 2023, under Application No. 18/225,452.

*For further information, inc...